Frontage Holdings Corporation (1521.HK)

HKSE • Market Data in HKD, Fundamentals in USD

$1.44

-$0.01

-0.69%

Last Update: 1 Sept 2025, 03:30

$2.93B

Market Cap

0.00

P/E Ratio (TTM)

—

Forward Dividend Yield

$0.47 - $1.87

52 Week Range

1521.HK Stock Price Chart

Explore Frontage Holdings Corporation interactive price chart. Choose custom timeframes to analyze 1521.HK price movements and trends.

1521.HK Company Profile

Discover essential business fundamentals and corporate details for Frontage Holdings Corporation (1521.HK) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

30 May 2019

Employees

1.56K

Website

https://www.frontagelab.com

CEO

Zhongping Lin

Description

Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services that include study designs, execution of studies, and interpretation of the data through structural optimization in early discovery, pharmacokinetic studies in rodents, non- GLP bioanalytical studies, etc. The company also provides safety and toxicology services comprising in-vitro and in-vivo studies; bioequivalence services, which consist of designing, coordinating, and reporting of bioequivalence studies; chemistry services comprising contract research and custom synthesis services; and clinical services, such as early stage clinical, BE/BA, biometric, and data management services. It operates in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.

1521.HK Financial Timeline

Browse a chronological timeline of Frontage Holdings Corporation corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 25 Mar 2026

Earnings released on 28 Aug 2025

EPS came in at $0.03 , while revenue for the quarter reached $993.94M , beating expectations by +1.64%.

Earnings released on 27 Mar 2025

EPS came in at $0.00 falling short of the estimated $0.08 by -95.53%, while revenue for the quarter reached $982.09M , missing expectations by -11.32%.

Earnings released on 20 Sept 2024

EPS came in at -$0.00 , while revenue for the quarter reached $1.00B .

Earnings released on 28 Mar 2024

EPS came in at $0.02 falling short of the estimated $0.08 by -69.94%, while revenue for the quarter reached $1.03B , missing expectations by -56.20%.

Earnings released on 27 Oct 2023

EPS came in at $0.02 , while revenue for the quarter reached $1.01B , missing expectations by -5.49%.

Earnings released on 28 Mar 2023

EPS came in at $0.05 falling short of the estimated $0.08 by -38.08%, while revenue for the quarter reached $1.03B , missing expectations by -58.67%.

Earnings released on 25 Aug 2022

EPS came in at $0.05 falling short of the estimated $0.08 by -38.54%, while revenue for the quarter reached $933.17M , missing expectations by -0.60%.

Earnings released on 29 Mar 2022

EPS came in at $0.04 falling short of the estimated $0.08 by -54.74%, while revenue for the quarter reached $774.40M , missing expectations by -4.25%.

Earnings released on 26 Aug 2021

EPS came in at $0.03 , while revenue for the quarter reached $660.98M , beating expectations by +6.38%.

Earnings released on 30 Mar 2021

EPS came in at $0.05 falling short of the estimated $0.08 by -38.34%, while revenue for the quarter reached $582.64M , beating expectations by +6.04%.

1521.HK Stock Performance

Access detailed 1521.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.